Complex karyotype in unfit patients with CLL treated with ibrutinib and rituximab: the GIMEMA LLC1114 phase 2 study

Blood. 2021 Dec 23;138(25):2727-2730. doi: 10.1182/blood.2021011883.
No abstract available

Publication types

  • Clinical Trial, Phase II
  • Letter
  • Multicenter Study
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Adenine / adverse effects
  • Adenine / analogs & derivatives*
  • Adenine / therapeutic use
  • Aged
  • Antineoplastic Combined Chemotherapy Protocols / adverse effects
  • Antineoplastic Combined Chemotherapy Protocols / therapeutic use*
  • Chromosome Aberrations / drug effects
  • Female
  • Humans
  • Karyotype
  • Leukemia, Lymphocytic, Chronic, B-Cell / drug therapy*
  • Leukemia, Lymphocytic, Chronic, B-Cell / genetics*
  • Male
  • Piperidines / adverse effects
  • Piperidines / therapeutic use*
  • Rituximab / adverse effects
  • Rituximab / therapeutic use*
  • Treatment Outcome

Substances

  • Piperidines
  • ibrutinib
  • Rituximab
  • Adenine